# Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

> clinical trial · VERIFIED · 2026-07-31

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Anal Basaloid Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: Anal Basaloid Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT03233711

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.